Waters Stock Price, News & Analysis

Waters Corporation (NYSE: WAT) reported fourth-quarter 2022 sales of $859 million, reflecting a 3% increase as reported and 9% in constant currency compared to Q4 2021. The full-year 2022 sales reached $2.97 billion, up 7% as reported and 12% in constant currency. Diluted EPS rose to $3.81 in Q4 2022 from $3.52 in Q4 2021. The company anticipates 2023 organic sales growth of 5% to 6.5% and non-GAAP EPS between $12.55 and $12.75, including a 3% foreign exchange headwind. Additionally, Waters announced the acquisition of Wyatt Technology for $1.36 billion, expected to close in Q2 2023, which will enhance its growth strategy.

Waters Corporation (NYSE:WAT) has announced the acquisition of Wyatt Technology for $1.36 billion. This strategic move is aimed at enhancing Waters’ growth by expanding its presence in high-growth adjacent markets, particularly in bioanalytical characterization related to cell and gene therapies. The acquisition is expected to be accretive to revenue and adjusted earnings per share starting Q1 2024, with projected revenue synergies exceeding $70 million by year five. Wyatt, with 2022 revenues of $110 million, brings significant expertise in light scattering technology, further bolstering Waters' analytical solutions portfolio.

Waters Corporation (NYSE:WAT) has launched the waters_connect System Monitoring application, a cloud-native Software-as-a-Service (SaaS) solution for real-time remote monitoring of chromatography instruments using Empower Software. This innovative tool enhances laboratory efficiency by providing immediate visibility into instrument availability, enabling quick response to changing priorities. It primarily targets high-volume QA/QC laboratories, assisting in reducing product release sample turnaround times and optimizing resource usage. The application is currently available in Europe and North America.

Waters Corporation (NYSE:WAT) will hold its Q4 2022 financial results conference call on February 15, 2023, at 8:00 a.m. eastern time. The live webcast can be accessed on their investor relations website. A replay will be available until March 1, 2023. Waters is a leader in analytical instruments and software, specializing in chromatography, mass spectrometry, and thermal analysis, with over 7,800 employees and operations in more than 35 countries.

Waters Corporation (NYSE:WAT) will present at the J.P. Morgan Healthcare Conference on January 9, 2023, at 4:30 PM PST. Udit Batra, CEO, will discuss key topics with investors. The event can be accessed via a live webcast on Waters' investor relations website, with a replay available for 30 days. Waters has been a leader in analytical instruments and software for over 60 years, specializing in chromatography and mass spectrometry, with a presence in over 100 countries and more than 7,800 employees.

Waters Corporation (NYSE:WAT) has appointed Dan Brennan and Mark Vergnano to its Board of Directors, effective November 23, 2022. Brennan, currently CFO at Boston Scientific, and Vergnano, former CEO of The Chemours Company, bring extensive experience crucial for Waters' growth strategy. Their addition follows a robust board refreshment process, making the board nine members strong, with eight independent. Chairman Dr. Flemming Ornskov highlights their potential to enhance operational and financial expertise as Waters implements its growth initiatives.

Waters Corporation has launched a new PFAS quantitation workflow that simplifies the detection of Per- and Polyfluoroalkyl Substances (PFAS) in various environmental samples. This end-to-end solution can measure parts-per-quadrillion (ppq) levels, exceeding regulatory limits, and includes automated data processing through the waters_connect software. This innovation aims to streamline laboratory operations while reducing manual errors in PFAS measurement, addressing increasing regulatory requirements.